Vaccinia virus mature virion surface and structural proteins (VACV MV surface proteins)

Vaccinia virus mature virion (MV) surface and structural proteins are a complex set of molecules that form the outer boundary of the primary infectious form of the virus. These proteins, such as L1, A27, H3, and D8, facilitate the initial attachment of the virus to host cell surface molecules like heparin sulfate and chondroitin sulfate (PMID: 15220411). Following attachment, a highly conserved group of eleven proteins known as the Entry Fusion Complex (EFC) mediates the fusion of the viral envelope with the host cell membrane (PMID: 22238261). These surface proteins are the principal targets for the host's neutralizing antibody response, making them critical components for vaccine design and passive immunotherapy. For instance, the L1 protein is a major target for neutralizing antibodies that can protect against orthopoxvirus challenges (PMID: 11832464). In the context of disease, these proteins enable the virus to infect a wide range of host cells, leading to conditions such as vaccinia infection, mpox, or historically, smallpox. Therapeutic strategies often involve the use of Vaccinia Immune Globulin Intravenous (VIGIV), which contains high titers of antibodies directed against these MV surface antigens to treat complications of vaccination (CDC, 2022). Understanding the structure and function of these proteins is essential for developing next-generation antivirals and safer vaccines.

Other names

VACV MV proteinsVaccinia virus membrane proteinsOrthopoxvirus surface antigensMV surface proteins

Neutralization of viral entry and inhibition of membrane fusion by binding to essential surface antigens.